Status:
COMPLETED
Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock
Lead Sponsor:
University of Zurich
Conditions:
Cardiogenic Shock
Cardiorenal Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
To determine whether Levosimendan infusion in patients with cardiogenic shock and cardiorenal syndrome refractory to standard inotropic therapy, improves hemodynamics and renal function, whilst being ...
Detailed Description
Cardiogenic Shock or the state of systemic hypoxia albeit initially preserved intra-vascular volume and intact vascular function, is solely the result of insufficient cardiac output \[1-2\]. The ensui...
Eligibility Criteria
Inclusion
- Levosimendan
- Cardiogenic Shock
- Continuous monitoring of cardiac output at the start of and during treatment with Levosimendan
Exclusion
- Extracorporal hemodynamic support or an implanted ventricular assist device
- Previous therapy with Levosimendan during the index hospitalization
- Refusal of participation in the study
Key Trial Info
Start Date :
June 30 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2014
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT04917497
Start Date
June 30 2011
End Date
April 30 2014
Last Update
June 8 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.